No Data
No Data
Allurion Technologies Announces New Study On Allurion Balloon And GLP-1 Agonists To Boost Long-Term Tolerability And Adherence; Previous Studies Show 30% GLP-1 Discontinuation in First Month, 58% Overall
Express News | Allurion Announces Plans to Combine GLP-1 Therapy With the Allurion Balloon to Treat Obesity
Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity
Analysts Offer Insights on Healthcare Companies: Outset Medical (OM) and Allurion Technologies (ALUR)
TD Cowen Maintains Allurion Technologies(ALUR.US) With Buy Rating, Maintains Target Price $16
Express News | Allurion Technologies: Ansm, French Regulatory Authority, Clears Allurion to Resume Sales of Allurion Balloon